Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

Howard Marks is much less skeptical about AI than he was just a few months ago. In December, Howard Marks published an investment memo titled, "Is it a bubble?" that expressed some of his skepticism ...

Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...

Tutorials might well be the bane of the video game industry's existence. Teaching a player how to do something is surprisingly difficult to do. Even if a developer crafts an educational and ...

This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...

Currently, the Python extension only supports “Run Selection/Line in Native Python REPL”. However, there is no built-in command to run the entire file in the Native Python REPL environment, similar to ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...